Multidrug-Resistant Aspergillus fumigatus Carrying Mutations Linked to Environmental Fungicide Exposure — Three States, 2010–2017

• Published in: MMWR. Morbidity and mortality weekly report Vol. 67; no. 38; pp. 1064 - 1067
• Main Authors: Beer, Karlyn D., Farnon, Eileen C., Jain, Seema, Jamerson, Carol, Lineberger, Sarah, Miller, Jeffrey, Berkow, Elizabeth L., Lockhart, Shawn R., Chiller, Tom, Jackson, Brendan R.
• Format: Journal Article Newsletter
• Language: English
• Published: United States Centers for Disease Control and Prevention 28.09.2018; U.S. Government Printing Office
• Subjects: Full Report; Genetic aspects; Health aspects; Microbial drug resistance; Molds (Fungi); Mycoses; Organ transplantation; Resveratrol; Stem cell transplantation; Stem cells; Triazoles; Pennsylvania
• ISSN: 0149-2195; 1545-861X
• DOI: 10.15585/mmwr.mm6738a5

The environmental mold Aspergillus fumigatus is the primary cause of invasive aspergillosis. In patients with high-risk conditions, including stem cell and organ transplant recipients, mortality exceeds 50%. Triazole antifungals have greatly improved survival (1); however, triazole-resistant A. fumigatus infections are increasingly reported worldwide and are associated with increased treatment failure and mortality (2). Of particular concern are resistant A. fumigatus isolates carrying either TR /L98H or TR /Y121F/T289A genetic resistance markers, which have been associated with environmental triazole fungicide use rather than previous patient exposure to antifungals (3,4). Reports of these triazole-resistant A. fumigatus strains have become common in Europe (2,3), but U.S. reports are limited (5). Because of the risk posed to immunocompromised patients, understanding the prevalence of such isolates in patients is important to guide clinical and public health decision-making. In 2011, CDC initiated passive laboratory monitoring for U.S. triazole-resistant A. fumigatus isolates through outreach to clinical laboratories. This system identified five TR /L98H isolates collected from 2016 to 2017 (6), in addition to two other U.S. isolates collected in 2010 and 2014 and reported in 2015 (5). Four of these seven isolates were reported from Pennsylvania, two from Virginia, and one from California. Three isolates were collected from patients with invasive pulmonary aspergillosis, and four patients had no known previous triazole exposure. A. fumigatus resistant to all triazole medications is emerging in the United States, and clinicians and public health personnel need to be aware that resistant infections are possible even in patients not previously exposed to these medications.